Topics

FDA Grants LN-145 Breakthrough Designation for Cervical Cancer

11:30 EDT 24 May 2019 | OncLive

The FDA has granted a breakthrough therapy designation to the tumor-infiltrating lymphocyte therapy LN-145 for the treatment of patients with recurrent, metastatic, or persistent cervical cancer with disease progression on or after chemotherapy. 
 

Original Article: FDA Grants LN-145 Breakthrough Designation for Cervical Cancer

NEXT ARTICLE

More From BioPortfolio on "FDA Grants LN-145 Breakthrough Designation for Cervical Cancer"

Quick Search

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Cervical Cancer
Cervical cancer is a malignant neoplasm of the cervix uteri or cervical area. Symptoms include vaginal bleeding, but may not present until later stages of the cancer. Cervical cancer can be treated using surgery (including local excision) in early stages...